NTHM's rebalance sold SaaS and batteries for obesity drugs and pipelines

The NBI Thematic Rotation ETF (NTHM:TSX) takes its orders from VettaFi's Thematic Rotation Quality Momentum Screened Index, and in the latest rebalance that index sold battery technology and storage and software-as-a-service to buy GLP-1 weight-loss drug manufacturers and midstream energy, according to ETF Trends.

Both arriving themes land at size: midstream energy takes 16.03% of NTHM across 22 holdings, ONEOK, Williams Companies, Kinder Morgan, Enbridge and TC Energy among them, a pipeline, storage, transportation and processing cohort that sits apart from exploration and production companies. GLP-1 enters at 14.41% across 18 holdings anchored by Eli Lilly, Novo Nordisk, AstraZeneca, Roche and Gilead Sciences, a roster described as drug developers and manufacturers plus the broader pharmaceutical ecosystem surrounding weight-management therapies; Lilly and Novo may be the obvious names, but Roche, AstraZeneca and Gilead sharing the slot shows how elastic a theme label gets once an index defines the category around an ecosystem rather than a molecule.

With midstream, GLP-1 and e-sports together at 45.11% of the fund, gaming held its place at 14.67% across 14 stocks — Meta Platforms, Microsoft, Tencent, Nintendo and Sony among them, a list the source says reaches well beyond game publishers — while battery and SaaS lost the same vote. The screen keeps what still moves and drops what has stopped, and no manager signs the sell ticket.

Advisors who want the obesity trade without seven themes wrapped around it can buy Amplify's Weight Loss Drug & Treatment ETF (THNR), which tracks the VettaFi Weight Loss Drug & Treatment Index at a 0.59% expense ratio and concentrates on drug developers and biotechnology companies. Our September coverage of THNR's rebalance recorded Gilead and Structure Therapeutics entering a 20-stock index and a $5.8 million fund whose return still rides on Eli Lilly. One wrapper bundles the theme into a diversified portfolio; the other is the theme, and it is small.

The rulebook is the product, as this publication argued when this rebalance landed: one pass took technology from 40.78% to 25.20% and handed the energy and healthcare sleeves to pipelines and GLP-1 makers. That design buys a theme after it has run, which is the honest case for a rotation index and the reason the GLP-1 weight carries no view on obesity-drug economics — it records which stocks were moving when the screen ran. The pipeline addition points the same way, because the midstream bid has been read as income buyers accepting underperformance for yield, and a momentum screen now carrying 16.03% in midstream suggests that bid is registering on price alone, inside a sleeve that never mentioned a distribution. The 22 pipelines now sit in a slot the index can exit as quickly as it entered.